Search Results
Your search for ,New matches 16919 pages
Showing 2301 - 2350Retrospective View of Medical Dissection From May 1896
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Assessing Geriatric Oncology Practice in Portugal
The global population is aging rapidly. Currently, there are more than 703 million people worldwide aged 65 and older, representing 9.1% of the global population. It is estimated that this percentage will grow to 15.9%—1.5 billion people—by 2050.1 And with that growing aging population will come...
ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1...
Second Annual Conference at the Nixon Presidential Library and Museum Emphasizes Patients’ Concerns
On December 23, 1971, President Richard Nixon signed the National Cancer Act of 1971 into law, establishing a national cancer program that included the National Cancer Institute (NCI), other research institutes, and federal and nonfederal programs; funding for 15 new cancer research centers and...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
A European Leader in Surgical Oncology, Isabel T. Rubio, MD, PhD, Shares Her Story and Sheds Light on the Challenges Ahead
In this installment of The ASCO Post’s Global Oncology series, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Isabel T. Rubio, MD, PhD, Head of Breast Surgical Oncology at Clinica Universidad de Navarra, Madrid. Dr. Rubio is active in many societies and is a founding member and...
Lobular vs Ductal Breast Cancer: Distinctions in Management
As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
Expert Point of View: Kohei Shitara, MD and Bradley Alexander McGregor, MD
At the ASCO session on the phase II DESTINY-PanTumor02 trial on T-DXd, the invited discussant, Kohei Shitara, MD, commented: “As expected, this trial demonstrated a very impressive response rate and duration of response” and “showed T-DXd [fam-trastuzumab deruxtecan-nxki] to be a potential new...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Expert Point of View: Mark Awad, MD, PhD
Formal discussant of KEYNOTE-671, Mark Awad, MD, PhD, of the Dana-Farber Cancer Institute, Boston, was optimistic about these data. “A hazard ratio of 0.58 for event-free survival and signals favoring overall survival in stage II to III non–small cell lung cancer [NSCLC] are truly impressive....
KEYNOTE-671 Trial: Perioperative Pembrolizumab Plus Chemotherapy Improves Outcomes in Stage II and III NSCLC
Neoadjuvant therapy with pembrolizumab plus platinum-based chemotherapy followed by surgery and then adjuvant pembrolizumab led to significantly improved event-free survival in patients with resectable stage II and III non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy...
CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
Expert Point of View: Pamela L. Kunz, MD and Corrie Marijnen, MD, PhD
Commenting at a press briefing, Pamela L. Kunz, MD, Director of the Center for Gastrointestinal Cancers and Chief of GI Medical Oncology at Smilow Cancer Hospital and Yale Cancer Center, New Haven, said the results of PROSPECT are “practice-changing” and “align incredibly well with the theme at...
PROSPECT Trial: Pelvic Radiation Therapy Avoided for Most Patients With Intermediate-Risk, Locally Advanced Rectal Cancer
Patients with intermediate-risk rectal cancer who received neoadjuvant chemotherapy with selective use of pelvic chemoradiation therapy had disease-free survival that was noninferior to the standard approach using pelvic chemoradiation, according to findings from the randomized phase III PROSPECT...
Adjuvant Osimertinib Improves Overall Survival in Resectable EGFR-Mutated NSCLC
The phase III ADAURA trial previously found that adjuvant use of osimertinib improved disease-free survival for completely resected EGFR-mutated non–small cell lung cancer (NSCLC) in patients with stage IB, II, or IIIA disease.1 The final analysis of ADAURA, which was presented at the 2023 ASCO...
Investigators Evaluate the Role of BMI in Outcomes in Patients With Head and Neck Cancer
Investigators have found that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those with a normal or obese BMI, according to a new study published...
Robotic-Assisted Resection of Challenging Gastric GISTs May Be Safe and Effective
Robot-assisted resection may be safe and effective at removing difficult-to-reach gastric gastrointestinal stromal tumors (GISTs), according to a novel study published by Lwin et al in the Journal of Surgical Research. Background For gastric GISTs, surgery is the standard treatment option; however, ...
Medicaid Expansion May Be Linked to Increase in Palliative Care for Patients With Advanced Cancers
The expansion of Medicaid coverage under the Affordable Care Act may be associated with the largest increases in critical palliative care services for patients with advanced cancers in the United States, according to a new study published by Han et al in Health Affairs. The findings uncovered how...
Aaron T. Gerds, MD, on Anemia in Myelofibrosis: New Data on Treatment With Luspatercept
Aaron T. Gerds, MD, of Cleveland Clinic Taussig Cancer Institute, talks about treating the anemia many patients with myelofibrosis experience because of JAK inhibitor therapy. The ACE-536-MF-001 study showed that luspatercept improved anemia and transfusion burden in this population, with a safety...
Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC
In the Spanish phase II NADIM II trial reported in The New England Journal of Medicine, Mariano Provencio, MD, PhD, and colleagues found that the addition of nivolumab to platinum-based chemotherapy improved pathologic complete response (pCR) rates among patients with resectable stage IIIA or IIIB...
COVID-19 Booster Doses May Strengthen Immunity in Patients With Lymphoma
Researchers have found that repeated COVID-19 vaccination may increase the vaccine’s effectiveness at preventing the infections in patients with lymphoma, particularly after four doses, according to a new study published by Wijaya et al in The Lancet. Background Patients with lymphoma often have...
Staging Laparoscopy May Help Identify Early Metastases in Patients With Pancreatic Cancer
Performing a minimally invasive staging laparoscopy on patients with newly diagnosed pancreatic cancer may help determine the stage and identify cancer metastases early, according to a novel study published by Gudmundsdottir et al in the Journal of the American College of Surgeons. The new findings ...
Patients Whose Pancreatic Cysts Remain Stable for 5 Years May Have Decreased Risk of Pancreatic Cancer
Investigators have called into question the health benefit of extended surveillance for patients whose pancreatic cysts have not changed size for at least 5 years and had no worrisome features, according to a new study published by Chhoda et al in Clinical Gastroenterology and Hepatology....
Investigators Identify Requirements to Potentially Optimize Cancer Survivorship Care for Patients in Rural Areas
The vast majority of cancer survivors may rely on primary care physicians for follow-up treatments, especially in rural areas, according to a new study published by Becevic et al in the Journal of Cancer Education. Background Patients often depend on their primary care physicians to help them...
Personalized Dosing May Improve Outcomes in Patients With Prostate Cancer
Physicians may be able to personalize dosing intervals and consequently improve patient outcomes by monitoring early-response biomarkers in patients with prostate cancer who are undergoing treatment with lutetium (Lu)-177–PSMA, according to new findings presented by Emmett et al at the Society of...
First-Line Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
As reported in the Journal of Clinical Oncology by O’Donnell et al, findings in a cohort of the phase Ib/II EV-103/KEYNOTE-869 study showed durable responses with first-line enfortumab vedotin-ejfv plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial...
Posttransplantation Cyclophosphamide-Based GVHD Prophylaxis in Patients With Hematologic Cancers Undergoing Allogeneic HSCT
In the phase III BMT CTN 1703 trial reported in The New England Journal of Medicine, Bolaños‑Meade et al found that posttransplantation cyclophosphamide-based graft-vs-host disease (GVHD) prophylaxis improved GVHD-free, relapse-free survival vs standard prophylaxis in patients with hematologic...
Novel Radiotracer May Accurately Detect and Differentiate Renal Cell Carcinomas
The positron-emission tomography (PET) tracer zirconium (Zr)-89–DFO-girentuximab may accurately identify patients with clear cell renal cell carcinoma and differentiate the disease from other types of renal tumors, according to findings presented by Calais et al at the Society of Nuclear Medicine...
CDCP1 May Be an Effective Therapeutic Target for Patients With Metastatic Bladder Cancer
Researchers have identified a new potential therapeutic target—the cell-surface tumor antigen CUB domain–containing protein 1 (CDCP1)—for patients with all subtypes of metastatic bladder cancer, according to findings presented by Chopra et al at the Society of Nuclear Medicine & Molecular...
Largest Human Breast Cell Atlas to Date May Offer Insights Into Mammary Biology
Researchers have created the world’s largest and most comprehensive atlas of normal breast tissue—the Human Breast Cell Atlas—which may provide an unprecedented understanding of mammary biology and help identify therapeutic targets for diseases such as breast cancer, according to a recent study...
Fertility in Female Survivors Treated for Hodgkin Lymphoma as Children
Female survivors treated for Hodgkin lymphoma may face declining fertility at a younger age, according to recent findings presented by Drechsel et al at the European Society of Human Reproduction and Embryology (ESHRE) 2023 Annual Meeting (Abstract O-083). The new research also suggested that the...
Direct Oral Anticoagulants vs Low–Molecular-Weight Heparin in Preventing Recurrent VTE in Patients With Cancer
In the CANVAS study, reported in JAMA, Deb Schrag, MD, FASCO, MPH, and colleagues found that use of direct oral anticoagulants was noninferior to low–molecular-weight heparin in preventing recurrent venous thromboembolism (VTE) in patients with cancer. Study Details In the open-label trial, 671...
LGBTQ+ Patients and Survivors of Cancer Expressed Concern Over Discrimination in Health-Care Settings, According to New Survey
About 50% of LGBTQ+ patients and survivors of cancer may be concerned about facing discrimination in a health-care setting, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). The new findings demonstrated that these concerns and experiences with...
Curettage and Cryosurgery May Be Effective for Patients With Basal Cell Carcinoma
The combination of curettage and cryosurgery may be a safe and effective treatment method for patients with basal cell carcinoma, according to a novel study published by Backman et al in the Journal of the American Academy of Dermatology. Background The incidence of skin cancer is continuing to...
Biden-Harris Administration Launches Initiative to Improve Cancer Outcomes in Low-Income Areas
On June 26, 2023, the Biden-Harris Administration awarded $50 million in the launch of the Persistent Poverty Initiative—a program designed to alleviate the cumulative effects of persistent poverty on cancer outcomes by increasing research capacity, fostering cancer prevention research, and...
FDA Approves Iopromide Injection for Contrast-Enhanced Mammography
Iopromide-300 and -370 (Ultravist), an iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography—making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of...
Potential Role of ChatGPT-4 in Selecting Appropriate Imaging Tests for Breast Cancer Screenings and Breast Pain
Investigators have found that artificial intelligence (AI) language models like OpenAI’s ChatGPT may accurately identify appropriate imaging tests for breast cancer screenings and breast pain, according to a recent study published by Rao et al in the Journal of the American College of Radiology....
Endometrial Cancer Risks and Trends Among Different Populations of African Descent
Women of African descent may have an elevated risk of being diagnosed with advanced endometrial cancer and developing aggressive tumors compared with White women, according to a recent study published by Medina et al in Cancer. Background Endometrial cancer is classified as endometrioid or the more ...
Pembrolizumab/Olaparib vs Next-Generation Hormonal Agents in Previously Treated Patients With Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Emmanuel S. Antonarakis, MD, and colleagues, the phase III KEYLYNK-010 trial has shown no improvement in survival outcomes with pembrolizumab/olaparib vs a next-generation hormonal agent (abiraterone or enzalutamide) in previously treated patients...
Role of Chemotherapy in Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Radiotherapy
In an updated individual patient data network meta-analysis reported in The Lancet Oncology, Petit et al found that the treatment approach with the highest overall survival benefit among patients with nonmetastatic nasopharyngeal carcinoma treated with radiotherapy was induction chemotherapy with...
Pretherapy Imaging and Dosimetry May Inform Personalized Treatment Strategies for Patients With Refractory Differentiated Thyroid Cancer
A combination of pretherapy imaging and dosimetry may help patients with refractory differentiated thyroid cancer obtain the maximum benefit from radioactive iodine treatments following redifferentiation therapy, according to a novel study published by Taprogge et al in The Journal of Nuclear...
EGFR and ERBB2 Mutations May Be Associated With Lenvatinib-Resistant Hepatocellular Carcinoma
A genetic marker involving the EGFR and ERBB2 genes may be predictive of which patients with hepatocellular carcinoma are most likely to develop resistance to lenvatinib, according to a study published by Lim et al in Gastroenterology. The new findings could help researchers develop alternative...
Ivy Brain Tumor Center Appoints New Chief Medical Officer
Yoshie Umemura, MD, was recently appointed as Chief Medical Officer of the Ivy Brain Tumor Center and Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute. Dr. Umemura plans to build on the Ivy Center’s clinical trials program and...
Certain Cancers Will Likely Rise Exponentially Because of COVID-19 Screening Delays, Study Predicts
Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have been caught earlier with screening. These cases may now be diagnosed at later stages, placing an increased burden on an already-strained health-care system, according to...
Immune Checkpoint Inhibitors Show Promise for People Living With HIV
New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published in the Journal of Clinical Oncology.1 The real-world data...
Retrospective Study Finds Black Patients With Colorectal Cancer Had Fewer Actionable Genomic Mutations Than White Patients
Black individuals have a higher incidence of colorectal cancer than White individuals, and their outcomes are worse. Undoubtedly, reasons for this are multifaceted, but the disparity in outcomes may be partly explained by genomic differences, documented in a large retrospective study presented at...
Guideline Update Provides New Testing and Treatment Recommendations for Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Mutations
Testing for the emergence of ESR1 mutations should be routine at disease recurrence or progression for patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer whose disease is being managed with endocrine therapy, according to an ASCO guideline rapid recommendation...
ASCO Issues Clinical Guidance for Treating Gastrointestinal Cancers Amid Acute Drug Shortages
ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal, pancreatic,...
